Drug Trial Radar · NCT03691519
Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
774
Actual
Start
Apr 17, 2018
Primary completion
Mar 31, 2020
Study completion Mar 31, 2020
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 1, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LO MAPT is an 18-month, phase III, multicenter, randomized, placebo-controlled, 2 parallel groups trial, followed by a 18-month open-label extension phase, to evaluate the efficacy of omega-3 supplementation on cognitive decline in older adults with low DHA/EPA status and subjective memory complaints or family history of Alzheimer disease.
Conditions
- Alzheimer Disease
Interventions
Omega-3 treatmentDrug
Patient in the "treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
PlaceboDietary supplement
The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil. 36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day). For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline of Composite Z-score which evaluate cognitive performanceTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Toulouse
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.